Summarized by Masters of Longevity from Longevity Docs News.
Senolytic treatment in people with fibrotic fatty liver disease: a short trial write-up that previews study design, biopsy endpoints, and cautious implications.
Key Takeaways
- Dasatinib plus quercetin improved fibrosis by at least one histologic stage in 47% of treated patients versus 7% on placebo.
- The trial enrolled 31 adults with biopsy-proven fibrotic metabolic dysfunction-associated steatohepatitis and used paired end-of-study biopsies.
- Treatment was intermittent dasatinib 100 mg plus quercetin 1,000 mg three days per week across three cycles over 21 weeks and had limited sample size and follow-up.
